Loading...
•
Jun 30, 2024
Delcath Q2 2024 Earnings Report
Reported $7.8 million in quarterly revenue.
Key Takeaways
Delcath Systems reported a significant increase in revenue for the second quarter of 2024, driven by sales of HEPZATO KIT™ and CHEMOSAT. The company is focused on expanding the adoption of HEPZATO KIT and advancing its clinical programs.
Recognized second quarter revenue of $6.6 million from HEPZATO KIT and $1.2 million from CHEMOSAT sales.
Activated three HEPZATO KIT treating centers in the US during the second quarter, with an additional center in July, totaling eight active centers.
Received New Technology Add-on Payment status (NTAP) for HEPZATO from CMS effective August 1, 2024.
Submitted the final principal payment due to Avenue Venture Opportunities Fund, L.P. on August 1, 2024.
Revenue by Segment
Forward Guidance
Delcath is optimistic about the continued adoption of HEPZATO KIT and its potential as a key therapeutic approach for metastatic uveal melanoma patients.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...